没食子酸表没食子儿茶素酯对唐氏综合征个体身体成分和脂质谱的影响：对临床管理的启示。

Effect of epigallocatechin gallate on the body composition and lipid profile of down syndrome individuals: Implications for clinical management.

机构信息

Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain; Cellular & Systems Neurobiology, Systems Biology Program, Centre for Genomic Regulation, The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain; Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.

Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain.

出版信息

Clin Nutr. 2020 Apr;39(4):1292-1300. doi: 10.1016/j.clnu.2019.05.028. Epub 2019 Jun 8.

DOI:10.1016/j.clnu.2019.05.028

PMID:31229326

Abstract

BACKGROUND & AIMS: Individuals with Down syndrome (DS) have higher rates of obesity. In the general population green tea extracts, and in particular epigallocatechin gallate (EGCG), have been studied for their antiobesogenic effects. The aim of this study is to elucidate the effect of EGCG on body weight in young DS adults and whether it could be related to changes in lipid profile.

METHODS

In the context of a double-blind phase II clinical trial comparing the effect of EGCG to that of placebo, the body composition of 77 young adults with DS was analyzed through bioelectrical impedance analysis. Lipids were analyzed using standard laboratory procedures. The factors tested in the ANCOVA model for the differences from baseline were treatment, sex as well as their interaction as independent variables. Baseline values were included in the models as covariates.

RESULTS

Individuals receiving placebo showed an increase in body weight and body mass index (BMI) that was not detected in those with EGCG treatment. EGCG effect on body composition was mainly observed in males, with significant differences between the EGCG and the placebo group after 12 months for weight (estimated adjusted mean difference (AMD) = -2.34, 95% CI = [-4.21, -0.48]; p = 0.015) and body fat (estimated AMD = -1.23, 95% CI = [-2.43,-0.04], p = 0.043). The changes detected in body composition were associated with changes in lipid profile.

CONCLUSIONS

Our results suggest that EGCG could have a modest beneficial effect on weight management in DS. Furthermore, EGCG has also a sex-dependent effect on lipid profile that is related to changes in body mass and composition.

摘要

背景与目的

唐氏综合征（DS）患者肥胖率较高。在普通人群中，绿茶提取物，特别是表没食子儿茶素没食子酸酯（EGCG），已被研究用于其抗肥胖作用。本研究旨在阐明 EGCG 对年轻 DS 成人体重的影响，以及它是否与血脂谱的变化有关。

方法

在一项比较 EGCG 与安慰剂效果的双盲二期临床试验中，通过生物电阻抗分析对 77 名年轻 DS 成年人的身体成分进行了分析。使用标准实验室程序分析脂质。在协方差分析模型中，将治疗、性别及其相互作用作为自变量，从基线的差异进行检验。将基线值作为协变量纳入模型。

结果

接受安慰剂的个体体重和体重指数（BMI）增加，而接受 EGCG 治疗的个体则未检测到这种增加。EGCG 对身体成分的影响主要在男性中观察到，在 12 个月后，EGCG 组与安慰剂组之间的体重差异有统计学意义（估计调整平均差异（AMD）= -2.34，95%CI = [-4.21，-0.48]；p = 0.015）和体脂肪（估计 AMD = -1.23，95%CI = [-2.43，-0.04]，p = 0.043）。身体成分的变化与血脂谱的变化有关。